Adi Treasurywala
Eastman Kodak Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adi Treasurywala.
Biochemical Pharmacology | 1996
David G. Sawutz; Donald C. Bode; G.Maurice Briggs; John Reid; Paul C. Canniff; Lisa Caldwell; Connie R. Faltynek; Deborah Miller; Joseph A. Dunn; Lawrence de Garavilla; Joseph Guiles; Carolyn Weigelt; William F. Michne; Adi Treasurywala; Paul J. Silver
In this report, we describe the discovery and characterization of a novel biarylhydrazone series of platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitors typified by the prototype WIN 41662 (3-phenyl-N1-[1-(4-pytidyl)pyrimidine]hydrazone). WIN 41662 inhibited PDGF-stimulated autophosphorylation of PDGF receptors from human vascular smooth muscle cells (hVSMC) with an IC50 value of 60 nM. The inhibitor appeared to be competitive with respect to substrate (Mn(2+)-ATP), having a calculated Ki of 15 +/- 5 nM. WIN 41662 was approximately 500-fold more potent in inhibiting the PDGF receptor tyrosine kinase than the p56lck tyrosine kinase. It was inactive against other serine/threonine and tyrosine kinases tested. WIN 41662 produced concentration-dependent inhibition of PDGF-stimulated receptor autophosphorylation in intact hVSMC with an IC50 < 100 nM. Intracellular Ca2+ mobilization and cell proliferation were events that occurred in hVSMC subsequent to PDGF receptor activation. WIN 41662 inhibited PDGF-stimulated Ca2+ mobilization and cell proliferation ([3H]TdR incorporation) with IC50 values of 430 nM and 2.3 microM, respectively. These effects appeared to be specifically related to PDGF receptor tyrosine kinase inhibition since WIN 41662 was not cytotoxic (in vitro) and since WIN 72039, a close structural analog that does not inhibit PDGF receptor tyrosine kinase, also did not inhibit PDGF-stimulated receptor autophosphorylation, Ca2+ mobilization, or hVSMC proliferation. Thus, WIN 41662 is representative of a novel class of selective PDGF receptor tyrosine kinase inhibitors that inhibit PDGF-regulated secondary events in intact cells.
Tetrahedron Letters | 1995
Robert B. Perni; Paul Kowalczyk; Adi Treasurywala; Michael Tracy
Abstract Molecular orbital calculations were carried out for pyridine-1-oxide and to determine the level of theory required to accurately represent the NO bond. The results clearly show that semi-empirical calculations fail to reproduce experimental values for bond lengths in pyridine-1-oxide. Lower level ab initio basis sets also provided poor results. STO-6-31G ∗∗ does, however provide good agreement with experiment for the NO bond lengths of pyridine-1-oxide.
Journal of Virology | 1989
Daniel C. Pevear; M J Fancher; Peter J. Felock; Michael G. Rossmann; M S Miller; Guy D. Diana; Adi Treasurywala; Mark A. McKinlay; Frank J. Dutko
Journal of Medicinal Chemistry | 1984
Kazimir Sestanj; Francesco Bellini; Steven Fung; Nedumparambil Abraham Abraham; Adi Treasurywala; Leslie G. Humber; N. Simard-Duquesne; D. Dvornik
Archive | 1981
Kazimir Sestanj; Nedumparambil Abraham Abraham; Francesco Bellini; Adi Treasurywala
Journal of Medicinal Chemistry | 1995
William F. Michne; Joseph Guiles; Adi Treasurywala; Laurie A. Castonguay; Carolyn Weigelt; Bernard O'Connor; Walter A. Volberg; Alison M. Grant; Christopher C. Chadwick; Douglas S. Krafte; Roger J. Hill
Journal of Medicinal Chemistry | 1992
Guy D. Diana; Paul Kowalczyk; Adi Treasurywala; Richard C. Oglesby; Daniel C. Pevear; Frank J. Dutko
Journal of Medicinal Chemistry | 1990
Guy D. Diana; Adi Treasurywala; Thomas R. Bailey; Richard C. Oglesby; Daniel C. Pevear; Frank J. Dutko
Journal of Medicinal Chemistry | 1988
Guy D. Diana; Michael J. Otto; Adi Treasurywala; Mark A. McKinlay; Richard C. Oglesby; Edward G. Maliski; Michael G. Rossmann; Thomas J. Smith
Journal of Medicinal Chemistry | 1989
John A. Butera; Jehan F. Bagli; Wendel Doubleday; Leslie G. Humber; Adi Treasurywala; Deborah A. Loughney; Kazimir Sestanj; Jane Millen; Janet Sredy